The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized trials of adjuvant tamoxifen versus tamoxifen and octreotide LAR in early-stage breast cancer: NCIC CTG MA.14 and NSABP B-29.
Judy-Anne W. Chapman
No relevant relationships to disclose
Joseph P. Costantino
No relevant relationships to disclose
Bin Dong
No relevant relationships to disclose
Richard G. Margolese
No relevant relationships to disclose
Kathleen I. Pritchard
No relevant relationships to disclose
Lois E. Shepherd
No relevant relationships to disclose
Karen A. Gelmon
No relevant relationships to disclose
Norman Wolmark
No relevant relationships to disclose
Michael N. Pollak
Research Funding - Novartis